Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Eloxatin, Oxaliplatin. Every FDA application for this active ingredient: 3 branded and 30 generic.
As of Nov 14, 2026, FDA lists 33 applications for Oxaliplatin (sold as Eloxatin, Oxaliplatin), first approved Aug 9, 2002, with 4 new uses approved and 0 published complete response letters.
First approved: Aug 9, 2002
Applications: 33
New uses approved: 4
Complete response letters: 0
Medicare spending, 2025: $2.6M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
ElplatDrugs with a new indication and a new dosage for the treatment of gastric cancer. · (1) Yakult Honsha Co., Ltd., (2) Sandoz K.K. · Mar 27, 2023
ElplatDrugs with a new indication and a new dosage for the treatment of small intestine cancer. · Daiichi Sankyo Espha Co., Ltd. · Sep 21, 2018
ElplatDrugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer. · Yakult Honsha Co., Ltd. · Mar 20, 2015
ElplatDrugs with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. · Yakult Honsha Co., Ltd. · Dec 20, 2013
ElplatDrugs with a new dosage for post-operative adjuvant chemotherapy for colon cancer. · Yakult Honsha Co., Ltd. · Nov 25, 2011
ElplatDrugs with a new additional indication and a new additional dosage and administration for combination therapy with other anticancer drugs (XELOX + BV… · Yakult Honsha Co., Ltd. · Sep 18, 2009
Elplat, new approvalDrugs with a new additional indication and a new dosage in an additional dosage form (Elplat I.V. · Yakult Honsha Co., Ltd. · Aug 20, 2009
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Sanofi Aventis US
Sandoz
Fresenius Kabi USA
Accord Hlthcare
Eugia Pharma
Mylan Labs Ltd